Dong-A ST (KOSPI 170900) 2026 stock outlook. A deep look at the IMULDOSA ustekinumab biosimilar with US and EU approvals, Intas and Accord licensing, the Growtropin growth-hormone franchise, diabetes and obesity pipeline, Korean drug-price pressure, and how it stacks up against Celltrion, Samsung Bioepis, Chong Kun Dang and Yuhan.
A qualitative 2026 outlook on Dongwha Pharmaceutical (KRX: 000020), Korea's oldest listed drugmaker. We unpack the century-old Gaswhalmyeongsu, Fucidin and Norumo OTC franchise, the generics and licensed-drug prescription business, its early-stage new-drug and biotech push, peer positioning, risks, and how international investors should size and tax a Korean small-cap cash cow.
SOOP (formerly AfreecaTV, KOSDAQ 067160) stock outlook for 2026. A qualitative deep dive into the high-margin Star Balloon gifting economy, sticky live communities, global SOOP expansion, the Chzzk competitive threat, top-streamer concentration, and gifting regulation risk.
Lotte Energy Materials (020150) stock outlook 2026. A qualitative deep dive into the former Iljin Materials, the world-class ultra-thin battery copper foil (Elecfoil) maker's moat, chasm-driven utilization pressure, Chinese oversupply, and Europe/US expansion risk.
SeAH Steel (KOSPI 306200) 2026 analysis for US investors: welded steel pipe and OCTG exports tied to US drilling and oil price, Section 232 quota and anti-dumping risk, the offshore-wind monopile growth leg, steel-spread volatility, and how it stacks up against Tenaris, Vallourec, Husteel and Nexteel.
Hansae Co. (105630) 2026 stock outlook: the knitwear OEM behind Nike, Gap, and Target, its Vietnam-Nicaragua-Indonesia production diversification, US tariff exposure, brand inventory-cycle risk, and how global investors can access this Korea-listed apparel manufacturer.
Hansol Chemical (014680) 2026 stock analysis: dominance in high-purity hydrogen peroxide for semiconductor and display fabs, QD display materials, silicon anode and battery binder growth bets, customer concentration on Samsung and SK hynix, and memory capex cycle exposure.
Dongwon Industries (KRX: 006040) 2026 stock outlook: a deep-sea tuna fishing fleet feeding StarKist, America's top canned-tuna brand, layered with a mid-tier holding structure over Dongwon Group's food and logistics affiliates. We unpack the moat, the price-fixing history, FX exposure, and the holding-company discount.
KSS Line (044450) 2026 stock analysis: how long-term contracts of affreightment (COA) stabilize cash flow for this Korean LPG/LNG/ammonia gas carrier operator, the ammonia-fuel optionality, and the newbuild price and charter-rate cycle risks investors need to weigh.
SD Biosensor (KOSPI 137310) 2026 stock analysis: normalizing revenue after the COVID rapid-test boom, the Meridian Bioscience acquisition, a large cash pile and capital allocation, POCT and molecular diagnostics diversification, and the Abbott/Roche competitive landscape.
A practical guide to choosing a structured settlement factoring company when selling future payments for a lump sum. Learn how discount rates set your real payout, how the mandatory court-approval process and state SSPA laws protect you, how to compare quotes, fees, and reputation, red flags to avoid, and alternatives like partial sales.
Cosmo Advanced Materials (Cosmo AM&T, KRX 005070) 2026 stock outlook: a qualitative deep dive into its high-nickel NCM cathode growth story, the steady cash flow of its MLCC release and toner film business, EV demand chasm exposure, lithium and nickel price pass-through, heavy capex financing risk, and how it stacks up against larger cathode makers like EcoPro and L&F.
A qualitative guide to what drives key person insurance cost for US small businesses: how premiums are set by age, health, coverage amount, and role, the price gap between term and permanent policies, how much coverage to buy, and the tax basics that shape true cost.
A qualitative guide to the multibillion-dollar 3M Combat Arms (CAEv2) earplug settlement framework: veteran eligibility, the point-based payout tiers, claims administration, disbursement timeline, deductions and liens, opt-out decisions, and how to choose a mass tort attorney.
ABNB (Airbnb) stock outlook for 2026. A deep qualitative analysis of the brand that became a verb, two-sided network effects and supply breadth as a moat, strong free cash flow and buybacks, and the structural risks of city STR regulation, core-growth maturity, and travel-demand cyclicality.
ASAN (Asana) 2026 stock outlook. A qualitative deep dive into the founder-led work-management SaaS: the enterprise up-market push, the AI Studio and AI teammates monetization bet, decelerating growth, path-to-profitability pressure, SMB churn, seat softness, SBC dilution, and rivals monday.com, Atlassian and Notion.
A qualitative 2026 stock outlook for Celltrion Pharm (KOSDAQ 068760): its role distributing the Celltrion group's biosimilars in Korea, the Cheongju chemical-drug business, group governance and related-party risk, a rich valuation versus earnings, and dependence on the parent.
COIN (Coinbase Global) 2026 stock outlook. A qualitative deep dive into the largest US-listed crypto exchange: cyclical transaction fees, the shift toward subscription and services revenue (USDC stablecoin share, custody, staking, Base L2), the regulatory-clarity tailwind, extreme earnings volatility, and why position sizing matters most.
A qualitative 2026 outlook on Dong Kook Pharmaceutical (KOSPI 086450): the Madecassol and Insadol OTC brand moat, prescription-drug stability, Centellian24 cosmetics and health-functional-food growth, home-shopping channel dependence, drug-pricing risk, and the dividend case.
Duksan Neolux (KOSDAQ 213420) 2026 stock outlook. A qualitative deep-dive into its OLED organic materials business (HTL, Red Host, Red Prime), the qualification moat as a core Samsung Display supplier, upside from OLED expansion into IT, foldables and automotive, plus customer-concentration and China panel-maker risks.
A 2026 guide to Errors and Omissions (E&O) insurance cost: what professional liability covers, who needs it, how premiums are priced by revenue, risk class, claims history and limits, E&O vs general liability vs professional indemnity, and proven ways to reduce your premium.
A qualitative deep dive into Hana Materials (KOSDAQ 166090) for 2026: the silicon and SiC etch-consumable business model, recurring revenue tied to fab utilization, exposure to NAND and logic wafer-start growth, plus the capex-cycle, customer-concentration, and SiC-competition risks investors must weigh.
IOT (Samsara) 2026 stock outlook. A qualitative deep dive into the Connected Operations Cloud, the sensor-hardware-plus-SaaS subscription model, net revenue retention, large-customer expansion, AI safety features, freight-cycle exposure, and valuation risk for physical-operations fleets.
071840 (Lotte Himart) stock outlook for 2026. A qualitative deep dive into Korea's largest consumer-electronics big-box retailer: store rationalization, private-brand and refurbished push, cost cuts, and margin recovery against Coupang-led e-commerce, plus deep-value asset and dividend angles.